Viridian Therapeutics, Inc.\DE (VRDN) Q3 2025 10-Q Quarterly Report
Viridian Therapeutics, Inc.\DE (VRDN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Viridian Therapeutics, Inc.\DE Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Potential failure to meet DRI Purchase and Sale Agreement milestones after October 2025, risking up to $245M in milestone payments
- • Updated clinical development risk: FDA may require additional patients beyond 300 in safety databases for veligrotug and VRDN-003, potentially delaying approvals
- • Regulatory risk: Post-approval obligations include costly phase 4 trials, REMS programs, and compliance inspections by FDA, EMA, and other authorities
- • Market risk: Commercial success dependent on third-party payor reimbursement, pricing, and market acceptance of products if approved
- • Financial risk: Cash $490.9M as of September 30, 2025 to fund operations 12+ months; additional capital likely needed, raising dilution and restrictive covenants concerns
Get deeper insights on Viridian Therapeutics, Inc.\DE
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.